FDA Approves Symbicort Asthma Combo Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved AstraZeneca's asthma therapy Symbicort (budesonide/formoterol) July 21 for patients 12 and older after a standard 10-month review
You may also be interested in...
AstraZeneca Wants COPD Label For Symbicort
Newly reported trials prove safety and efficacy, company says.
AstraZeneca Wants COPD Label For Symbicort
Newly reported trials prove safety and efficacy, company says.
AstraZeneca Will Acquire Verus Asthma Program In Deal Worth $310 Million
Agreement will allow AstraZeneca to continue building its pediatric respiratory franchise, firm tells "The Pink Sheet" DAILY.